A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

NCT06970119 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: INR102 injection

Sponsor

Yunhe Pharmaceutical (Tianjin) Co., Ltd